#### **ATENOLOL SHORTAGE**

Several generic brands of atenolol tablets 25mg, 50mg and 100 mg are approved for marketing by Health Canada (<a href="http://webprod5.hc-sc.gc.ca/dpd-bdpp/dispatch-repartition.do?lang=eng">http://webprod5.hc-sc.gc.ca/dpd-bdpp/dispatch-repartition.do?lang=eng</a>) and are on the Saskatchewan Drug Plan Formulary (<a href="http://formulary.drugplan.health.gov.sk.ca/">http://formulary.drugplan.health.gov.sk.ca/</a>)<sup>2</sup>.

## Health Canada approved indications<sup>3</sup>

- mild to moderate hypertension
- long-term management of angina pectoris due to ischemic heart disease

#### Off-label uses4

- post-myocardial infarction
- atrial fibrillation (rate control)
- migraine prophylaxis

#### Options to handle shortage of atenolol tablets:

- Evaluate the appropriateness of atenolol therapy. Evidence suggests that atenolol is less effective than certain other beta-blockers and drugs from other pharmacologic classes in reducing cardiovascular risk when used to treat hypertension, particularly in older adults. Atenolol has also been associated with increased mortality. This could be an opportune time to recommend switching atenolol to a more effective and safer alternative.
- **Extemporaneous compounding**: atenolol bulk powder is available (e.g. Medisca<sup>7</sup>) for compounding tablets or capsules.
- Therapeutic alternatives:

#### Beta-blockers,8,9:

| Indication                    | Recommended atenolol dose | Alternative(s)  |
|-------------------------------|---------------------------|---|
| Mild to moderate hypertension | 50 to 100 mg daily        | <ul> <li>Acebutolol 100 to 400 mg BID</li> <li>Bisoprolol 5 to 20 mg once daily</li> <li>Labetolol 100 mg to 600 mg BID</li> <li>Metoprolol RR 50 to 200 mg BID or 100 to 200 mg SR once daily</li> <li>Nadolol 40 to 320 mg daily</li> <li>Nebivolol 5 to 20 mg once daily</li> <li>Pindolol 5 to 15 mg BID or TID up to 45 mg daily.</li> <li>Propranolol RR 40 mg BID up to 320 mg daily or LA 60 to 320 mg daily</li> <li>Timolol 5 to 10 mg BID up to 60 mg daily</li> </ul> |
| Angina pectoris               | 50 to 200 mg once daily   | <ul> <li>Acebutolol 200 to 300 mg BID</li> <li>Metoprolol 50 to 200 mg BID or 100 to 200 mg SR once daily</li> <li>Nadolol 40 to 240 mg daily</li> <li>Pindolol 5 mg TID or QID up to 40 mg daily</li> </ul>  |

|   |                          | <ul> <li>Propranolol RR 10 to 20 mg TID or QID up to 240 mg daily or LA 80 mg daily up to 320 mg daily</li> <li>Timolol 5 mg BID or TID up to 45 mg daily</li> </ul>   |
|---|--------------------------|--|
| Post-myocardial infarction<br>(Non-approved indication for<br>atenolol) | Target 100 mg daily      | <ul> <li>Acebutolol target 400 mg BID</li> <li>Carvedilol target 25 mg BID</li> <li>Metoprolol target RR 100 mg BID; SR 200 mg once daily</li> <li>Nadolol target 160 mg daily</li> <li>Propranolol target RR 60 to 80 mg TID</li> <li>Timolol target 10 mg BID</li> </ul> |
| Atrial fibrillation<br>(Non-approved indication for atenolol)           | 50 to 150 mg once daily  | <ul> <li>Bisoprolol 2.5 to 20 mg once daily</li> <li>Metoprolol RR 25 to 200 mg BID or SR 100 mg daily to 200 mg BID</li> </ul>  |
| Migraine prevention (Non-approved indication for atenolol)              | 25 to 100 mg once daily) | <ul> <li>Metoprolol 50 to 200 mg daily</li> <li>Propranolol RR 80 to 320 mg daily; LA 120 mg daily<sup>11</sup></li> <li>Timolol 10 to 30 mg daily</li> </ul>  |

RR= regular release; SR= slow release, LA = long acting

### Alternatives from other pharmacologic classes 10,11:

(Note: if switching to another pharmacologic class, the atenolol must be tapered)

| Indication                       | Alternative pharmacologic class   |
|----------------------------------|---|
| Mild to moderate hypertension    | Diuretics, ACE inhibitors, ARBs, calcium channel blockers                     |
| Angina pectoris                  | Nitrates, calcium channel blockers, ACE inhibitors                            |
| Atrial fibrillation rate control | Nondihydropyridine calcium channel blockers                                   |
| Migraine prevention              | TCAs, anticonvulsants, venlafaxine, calcium channel blockers, ACE inhibitors, |
|                                  | pizotifen   |

# Prepared by Karen Jensen MSc, BSP; reviewed by Carmen Bell BSP medSask, Oct. 2014

#### References:

- Atenolol. Drug Product Database. Health Canada. Available at <a href="http://webprod5.hc-sc.gc.ca/dpd-bdpp/dispatch-repartition.do?lang=eng">http://webprod5.hc-sc.gc.ca/dpd-bdpp/dispatch-repartition.do?lang=eng</a>. Accessed Oct. 17, 2014.
- 2. Atenolol. Saskatchewan Drug Formulary. Available at http://formulary.drugplan.health.gov.sk.ca. Accessed Oct. 17, 2014.
- 3. Co atenolol monograph. Available at <a href="http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=74074&lang=eng">http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=74074&lang=eng</a>. Accessed Oct. 17, 2014
- 4. Atenolol. Lexicomp Online® , Lexi-Drugs® , Hudson, Ohio: Lexi-Comp, Inc. Accessed Oct. 17, 2014.
- 5. PL Detail-Document, Atenolol for Hypertension. Pharmacist's Letter/Prescriber's Letter. January 2013.
- 6. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004 Nov 6;364(9446):1684-9.
- 7. Medisca website. Available at <a href="http://www.medisca.com/en-ca/home.aspx">http://www.medisca.com/en-ca/home.aspx</a>. Accessed Oct 17, 2014.
- 8. e-CPS [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2014 [updated 2014 Feb; cited 2014 Oct 17]. Beta-adrenergic blocking agents. General monograph. Available from: <a href="http://www.e-cps.ca">http://www.e-cps.ca</a>.
- 9. PL Detail-Document, Comparison of Oral Beta-Blockers. Pharmacist's Letter/Prescriber's Letter. December 2012.
- 10. RxFiles Drug Comparison Charts. Available at <a href="www.rxfiles.ca">www.rxfiles.ca</a>. Accessed Oct. 17, 2014.
- 11. Gray Jean, editor. e-Therapeutics<sup>†</sup> [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2014 [updated....; cited 2014 Oct 17]. Available from: <a href="http://www.e-therapeutics.ca">http://www.e-therapeutics.ca</a>.